Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Nov 1;60(11):1795.
doi: 10.3390/medicina60111795.

The Trend of Changes in Adiponectin, Resistin, and Adiponectin-Resistin Index Values in Type 2 Diabetic Patients with the Development of Metabolic Syndrome

Almir Fajkić  1 , Rijad Jahić  2 , Malik Ejubović  3 , Miralem Đešević  4 , Amira Jagodić Ejubović  3 , Orhan Lepara  5
Affiliations
Observational Study

The Trend of Changes in Adiponectin, Resistin, and Adiponectin-Resistin Index Values in Type 2 Diabetic Patients with the Development of Metabolic Syndrome

Almir Fajkić et al. Medicina (Kaunas). .

Abstract

Background and Objectives: This study aimed to investigate the novel adiponectin-resistin (AR) index as a predictor of the development of metabolic syndrome (MetS) in individuals with type 2 diabetes mellitus (T2DM). MetS is common in T2DM and increases cardiovascular risk. Adiponectin and resistin, adipokines with opposing effects on insulin sensitivity and inflammation, make the AR index a potential marker for metabolic risk. Materials and Methods: This prospective observational study included 80 T2DM participants (ages 30-60) from Sarajevo, Bosnia and Herzegovina, over 24 months. The participants were divided into two groups: T2DM with MetS (n = 48) and T2DM without MetS (n = 32). Anthropometric data, biochemical analyses, and serum levels of adiponectin and resistin were measured at baseline and every six months. The AR index was calculated using the formula AR = 1 + log10(R) - 1 + log10(A), where R and A represent resistin and adiponectin concentrations. Logistic regression identified predictors of MetS. Results: T2DM patients who developed MetS showed a significant decline in adiponectin levels (40.19 to 32.49 ng/mL, p = 0.02) and a rise in resistin levels (284.50 to 315.21 pg/mL, p = 0.001). The AR index increased from 2.85 to 2.98 (p = 0.001). The AR index and resistin were independent predictors of MetS after 18 months, with the AR index showing a stronger predictive value (p = 0.007; EXP(B) = 1.265). Conclusions: The AR index is a practical marker for predicting MetS development in T2DM participants, improving metabolic risk stratification. Incorporating it into clinical assessments may enhance early detection and treatment strategies.

Keywords: AR index; adiponectin; metabolic syndrome; resistin; type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
T2DM participants’ selection flowchart.
Figure 2
Figure 2
Trends of changes in serum adiponectin concentrations in T2DM participants with and without MetS. The results are presented in percentages (%); T2DM: type 2 diabetes mellitus; MetS: metabolic syndrome; n: number of participants. * p < 0.05.
Figure 3
Figure 3
Trends of changes in serum resistin concentrations in T2DM participants with and without MetS. The results are presented in percentages (%); T2DM: type 2 diabetes mellitus; MetS: metabolic syndrome; n: number of participants; * p < 0.05.
Figure 4
Figure 4
Trends of changes in AR index values in T2DM participants with and without MetS. The results are presented in percentages (%); T2DM: type 2 diabetes mellitus; MetS: metabolic syndrome; n: number of participants; * p < 0.05.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Habib S.S., Al-Khlaiwi T., Butt M.A., Habib S.M., Al-Khliwi H., Al-Regaiey K. Novel Adiponectin-Resistin Indices and Ratios Predict Increased Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus. J. Saudi Heart Assoc. 2023;35:59–65. doi: 10.37616/2212-5043.1332. - DOI - PMC - PubMed
    1. Nsiah K., Shang V.O., Boateng K.A., Mensah F.O. Prevalence of metabolic syndrome in type 2 diabetes mellitus patients. Int. J. Appl. Basic Med. Res. 2015;5:133–138. doi: 10.4103/2229-516X.157170. - DOI - PMC - PubMed
    1. Asghar S., Asghar S., Shahid S., Fatima M., Bukhari S.M.H., Siddiqui S.M. Metabolic Syndrome in Type 2 Diabetes Mellitus Patients: Prevalence, Risk Factors, and Associated Microvascular Complications. Cureus. 2023;15:e39076. doi: 10.7759/cureus.39076. - DOI - PMC - PubMed
    1. Battineni G., Sagaro G.G., Chintalapudi N., Amenta F., Tomassoni D., Tayebati S.K. Impact of Obesity-Induced Inflammation on Cardiovascular Diseases (CVD) Int. J. Mol. Sci. 2021;22:4798. doi: 10.3390/ijms22094798. - DOI - PMC - PubMed
    1. Lee M.W., Lee M., Oh K.J. Adipose Tissue-Derived Signatures for Obesity and Type 2 Diabetes: Adipokines, Batokines and MicroRNAs. J. Clin. Med. 2019;8:854. doi: 10.3390/jcm8060854. - DOI - PMC - PubMed

Publication types

LinkOut - more resources